Correlation Between DiaMedica Therapeutics and Madrigal Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both DiaMedica Therapeutics and Madrigal Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining DiaMedica Therapeutics and Madrigal Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between DiaMedica Therapeutics and Madrigal Pharmaceuticals, you can compare the effects of market volatilities on DiaMedica Therapeutics and Madrigal Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in DiaMedica Therapeutics with a short position of Madrigal Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of DiaMedica Therapeutics and Madrigal Pharmaceuticals.

Diversification Opportunities for DiaMedica Therapeutics and Madrigal Pharmaceuticals

0.23
  Correlation Coefficient

Modest diversification

The 3 months correlation between DiaMedica and Madrigal is 0.23. Overlapping area represents the amount of risk that can be diversified away by holding DiaMedica Therapeutics and Madrigal Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Madrigal Pharmaceuticals and DiaMedica Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DiaMedica Therapeutics are associated (or correlated) with Madrigal Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Madrigal Pharmaceuticals has no effect on the direction of DiaMedica Therapeutics i.e., DiaMedica Therapeutics and Madrigal Pharmaceuticals go up and down completely randomly.

Pair Corralation between DiaMedica Therapeutics and Madrigal Pharmaceuticals

Given the investment horizon of 90 days DiaMedica Therapeutics is expected to generate 1.3 times more return on investment than Madrigal Pharmaceuticals. However, DiaMedica Therapeutics is 1.3 times more volatile than Madrigal Pharmaceuticals. It trades about 0.33 of its potential returns per unit of risk. Madrigal Pharmaceuticals is currently generating about 0.05 per unit of risk. If you would invest  425.00  in DiaMedica Therapeutics on September 2, 2024 and sell it today you would earn a total of  141.00  from holding DiaMedica Therapeutics or generate 33.18% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

DiaMedica Therapeutics  vs.  Madrigal Pharmaceuticals

 Performance 
       Timeline  
DiaMedica Therapeutics 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in DiaMedica Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, DiaMedica Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.
Madrigal Pharmaceuticals 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.

DiaMedica Therapeutics and Madrigal Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with DiaMedica Therapeutics and Madrigal Pharmaceuticals

The main advantage of trading using opposite DiaMedica Therapeutics and Madrigal Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if DiaMedica Therapeutics position performs unexpectedly, Madrigal Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Madrigal Pharmaceuticals will offset losses from the drop in Madrigal Pharmaceuticals' long position.
The idea behind DiaMedica Therapeutics and Madrigal Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Other Complementary Tools

Stocks Directory
Find actively traded stocks across global markets
Commodity Directory
Find actively traded commodities issued by global exchanges
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope